Latest membrane technology Stories

After Reviewing Brief Product Profiles, Surveyed Nephrologists Indicate Moderate to High Interest in Zerenex, SFP and PA21, According to a New Report from BioTrends Research Group EXTON, Pa., April 15, 2013 /PRNewswire/ -- BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that in hemodialysis (HD), Sanofi's Ferrlecit patient share has experienced a significant 9 percent increase between Q4 2012 and Q1...

U.S. panel of judges grants plaintiffs' petition seeking consolidation before a single judge of numerous lawsuits alleging Fresenius dialysis products were linked to kidney failures. Resource4thePeople offering free legal consultations. San Diego, CA (PRWEB) April 14, 2013 http://www.resource4thepeople.com/defectivemedicaldevices/Dialysis-Lawsuit.html Resource4thePeople reports today an update of the progress of numerous lawsuits* in the federal court system alleging that NaturaLyte...

Differences are especially pronounced in regions that spend the most on end-of-life care Highlights: -There is substantial regional variation in the magnitude of racial differences in end-of-life care among US adults with kidney failure. -Black-white differences in dialysis discontinuation and hospice referral are most pronounced in regions with the highest levels of end-of-life spending. More than 590,000 Americans in 2010 were treated for kidney failure. At the end of life,...

According to court documents, on March 6th, 2013 four class action lawsuits were filed alleging DaVita Healthcare should have known of the risks for serious adverse effects from Granuflo and Naturalyte. In light of these news, AttorneyOne, a recognized authority on law, informs that they are now providing advice, including how to get in contact with legal counsel, to people potentially affected by Granuflo side effects. San Diego, CA (PRWEB) April 09, 2013 AttorneyOne.com, a recognized...

"Living with Dialysis" information key resource on site BETHLEHEM, Pa., April 9, 2013 /PRNewswire/ -- B. Braun Medical Inc. (B.Braun) launched a new website for dialysis patients. The website, which can be found at www.bbraun-dialysis.com, provides information about living with dialysis. Patients will find useful tips on everyday topics, planning an overseas vacation, and be able to utilize this website to locate the addresses of over 200 dialysis centers worldwide to arrange...

Educational Summit to Highlight HeRO® Graft and Other Emerging Technologies to 75+ Healthcare Professionals Focused on End-Stage Renal Disease ATLANTA, April 8, 2013 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading tissue processing and medical device company focused on cardiac and vascular surgery, announced today that it will host a Central Venous Pathology (CVP) Summit on April 18-19, 2013 at CryoLife's training facility at its corporate headquarters in suburban Atlanta and...

Company to Leverage Recent CE Mark Approvals for System One Innovations LAWRENCE, Mass., April 8, 2013 /PRNewswire/ -- NxStage(®) Medical, Inc. (Nasdaq: NXTM), a leading manufacturer of innovative dialysis products, announced today that it has completed its move to a direct sales model in the United Kingdom. NxStage will begin selling the System One(TM) and related products and services directly in the region through its wholly-owned UK subsidiary, NxStage Medical UK, Ltd. The...

Osmosis – the flow of a solvent across a semipermeable membrane from a region of lower to higher solute concentration – is a well-developed concept in physics and biophysics. The problem is that, even though the concept is important to plant and human physiology, osmosis is understood in biology and chemistry in a much simpler – and often incorrect – way. "A range of surprising misconceptions about osmosis continue to appear in papers, web sites and textbooks," says Eric Kramer,...

EXTON, Pa., April 4, 2013 /PRNewswire/ -- BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that, compared to just one year ago, the mean hemoglobin at erythropoiesis-stimulating agent (ESA) initiation has significantly declined and is nearing levels at which a blood transfusion may be required. In addition, nephrologists tend to overestimate the percent of stage 3 chronic kidney disease (CKD) patients on...

New Adaptor Allows Use with Early Access Arterial Grafts ATLANTA, April 4, 2013 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading tissue processing and medical device company focused on cardiac and vascular surgery, announced today that it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for a next generation HeRO (Hemodialysis Reliable Outflow) device. The HeRO device is the only subcutaneous AV access solution clinically proven to maintain long-term access...